Background. We present outcome data from concurrent chemotherapy and intensity-modulated radiation therapy (IMRT) for squamous cell carcinoma (SCC) of the larynx and oropharyx. Methods. Eighty patients with laryngeal (n = 15) or oropharyngeal (n = 65) SCC underwent concurrent IMRT and chemotherapy (cisplatin or carboplatin/paclitaxel). Results. The 3-year overall survival (OS) and disease-free survival (DFS) were 81.2% and 78.3%, respectively, with a median follow-up of 31.2 months. There was a statistically significant correlation between OS and DFS with N classification (p = .0001), but not with disease site or T classification. Toxicities compared favorably with prior reports using conventional radiation therapy. Conclusions. This retrospective analysis reveals a very good outcome and an acceptable toxicity profile for patients with locally advanced SCC of the oropharynx and larynx treated with chemotherapy and IMRT concurrently.

, , , ,
doi.org/10.1002/hed.21120, hdl.handle.net/1765/75116
Head & Neck: journal for the sciences and specialities of the head and neck
Institute for Medical Technology Assessment (iMTA)

Saba, N., Edelman, D., Tighiouart, M., Gaultney, J. G., Davis, L., Khuri, F., … Shin, D. (2009). Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: A retrospective single-institution analysis. Head & Neck: journal for the sciences and specialities of the head and neck, 31(11), 1447–1455. doi:10.1002/hed.21120